- Under the terms of the research collaboration and exclusive option agreement, the companies will initiate a gene editing research program dedicated to the treatment of two early onset indications with high unmet need, leveraging the GeneRide™ platform -
top of page
Search
Recent Posts
See AllImmunoBrain Checkpoint Awarded $5 Million US NIA Grant for Phase 1b Alzheimer’s Disease Proof-of-Mechanism Study of Anti-PD-L1 IBC-Ab002...
MONMOUTH JUNCTION, N.J. and AIRPORT CITY, Israel, July 06, 2021 (GLOBE NEWSWIRE) -- Advaxis, Inc. (“Advaxis”) (NASDAQ: ADXS) and Biosight...
LogicBio Therapeutics Announces First Patient Dosed in Groundbreaking Phase 1/2 SUNRISE Clinical Trial for the Treatment of Pediatric...
bottom of page
Comments